Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s lead product is naporafenib which is in SEACRAFT-2 pivotal Phase 3 trial for patients with NRAS-mutated (NRASm) melanoma; and in SEACRAFT-1 Phase 1b trial for patients with NRAS Q61X melanoma. It also develops ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-altered solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-altered solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGRF and RAS/MAPK solid tumors. In addition, the company’s products under development include ERAS-801, a central nervous system (CNS)-penetrant EGFR inhibitor for patients with EGFR-altered recurrent glioblastoma (GBM) which is in phase 1 clinical trials; and ERAS-007, an oral inhibitor of ERK1/2 and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It has a license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
तुलना करने के लिए मीट्रिक्स | ERAS | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधERASपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −22.0x | −3.8x | −0.6x | |
PEG अनुपात | −0.50 | 0.05 | 0.00 | |
क़ीमत/बुक | 8.1x | 4.0x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 80.9x | 3.4x | |
अपसाइड (विश्लेषक लक्ष्य) | −48.0% | 95.5% | 41.5% | |
उचित मूल्य अपसाइड | अनलॉक करें | 5.9% | 5.5% | अनलॉक करें |